Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	19.73B +70.4%
Revenue (ttm)	5.36B +19.8%
Net Income	303.18M
EPS	0.61
Shares Out	575.98M
PE Ratio	55.98
Forward PE	n/a
Dividend	5.69 (16.50%)
Ex-Dividend Date	Jul 31, 2025

Volume	433,714
Open	34.48
Previous Close	34.50
Day's Range	33.34 - 34.48
52-Week Range	32.20 - 67.30
Beta	-0.12
Analysts	Buy
Price Target	14.95 (-56.36%)
Earnings Date	Aug 28, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 6,353
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error